JP2013541944A5 - - Google Patents

Download PDF

Info

Publication number
JP2013541944A5
JP2013541944A5 JP2013529675A JP2013529675A JP2013541944A5 JP 2013541944 A5 JP2013541944 A5 JP 2013541944A5 JP 2013529675 A JP2013529675 A JP 2013529675A JP 2013529675 A JP2013529675 A JP 2013529675A JP 2013541944 A5 JP2013541944 A5 JP 2013541944A5
Authority
JP
Japan
Prior art keywords
seq
chimeric antibody
subject
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013529675A
Other languages
English (en)
Japanese (ja)
Other versions
JP5946459B2 (ja
JP2013541944A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/066791 external-priority patent/WO2012041863A1/en
Publication of JP2013541944A publication Critical patent/JP2013541944A/ja
Publication of JP2013541944A5 publication Critical patent/JP2013541944A5/ja
Application granted granted Critical
Publication of JP5946459B2 publication Critical patent/JP5946459B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013529675A 2010-09-27 2011-09-27 腫瘍形成(neoplasia)を治療するための組成物および方法 Expired - Fee Related JP5946459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38676410P 2010-09-27 2010-09-27
US61/386,764 2010-09-27
PCT/EP2011/066791 WO2012041863A1 (en) 2010-09-27 2011-09-27 Compositions and methods for treating neoplasia

Publications (3)

Publication Number Publication Date
JP2013541944A JP2013541944A (ja) 2013-11-21
JP2013541944A5 true JP2013541944A5 (enExample) 2014-11-13
JP5946459B2 JP5946459B2 (ja) 2016-07-06

Family

ID=44675608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529675A Expired - Fee Related JP5946459B2 (ja) 2010-09-27 2011-09-27 腫瘍形成(neoplasia)を治療するための組成物および方法

Country Status (12)

Country Link
US (2) US9115192B2 (enExample)
EP (1) EP2621947A1 (enExample)
JP (1) JP5946459B2 (enExample)
KR (1) KR20140016240A (enExample)
CN (1) CN103459420B (enExample)
AU (1) AU2011310664B2 (enExample)
BR (1) BR112013007327A2 (enExample)
CA (1) CA2812644A1 (enExample)
IL (1) IL225483A0 (enExample)
MX (1) MX2013003561A (enExample)
SG (1) SG189095A1 (enExample)
WO (1) WO2012041863A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201427681A (zh) 2013-01-07 2014-07-16 Superlab Far East Ltd 用空間構象改變的重組干擾素治療腫瘤的方法
WO2015025786A1 (ja) * 2013-08-20 2015-02-26 独立行政法人科学技術振興機構 ヒト抗体κ型軽鎖複合体含有組成物及びその製造方法
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
CN107847564B (zh) * 2015-05-12 2021-11-09 远东超级实验室有限公司 鉴定对肿瘤具有直接抑制作用的干扰素的方法及其用途
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
AU2005306997B2 (en) * 2004-10-25 2012-07-05 Merck Sharp & Dohme Corp. Anti-ADDL antibodies and uses thereof

Similar Documents

Publication Publication Date Title
AU2013359167B2 (en) Therapeutic CD47 antibodies
ES2829206T3 (es) Moduladores novedosos y procedimientos de uso
JP2013502204A5 (enExample)
US10441587B2 (en) Treatment of lung cancer with inhibitors of glutaminase
JP2010523541A5 (enExample)
JP2010535713A5 (enExample)
JP2013515013A5 (enExample)
CN113045660A (zh) 与cd8的抗原结合构建体
JP2014511179A5 (enExample)
RU2007147596A (ru) Моноклональные антитела и одноцепочечные фрагменты антител против клеточно-поверхностного специфического для простаты мембранного антигена
JP2011507852A5 (enExample)
JP2019508013A5 (enExample)
JP2015221793A (ja) invivoで抗腫瘍活性を有する抗ヒトTROP−2抗体
CO6241160A2 (es) Anticuerpos anti-cd44 quiméricos y humanizados que median la citotoxicidad de celulas de cancer
JP2013506686A5 (enExample)
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
AU2011310664B2 (en) Compositions and methods for treating neoplasia
KR20210143804A (ko) 혈액암 및 고형 종양암의 치료를 위한 키메라 항원 수용체 변형된 t 세포 (car-t)
JP2018508229A5 (enExample)
JP2019501139A5 (enExample)
CN115103633B (zh) 使用多种成像剂的成像方法
JP2023518153A5 (enExample)
JP2015513919A (ja) 膵癌細胞への治療的送達および診断的送達のためのrnaアプタマー
JP2016513105A5 (enExample)
SI2905335T1 (en) Anti-human dlk-1 antibody having anti-tumor activity in vivo